About Ansa Research
Ansa Research is a Healthcare company based in Bengaluru (India) founded in 2009 by N K Venkataramana. It operates as a stem cell research and therapies for neurological disorders are developed. The company has 18 employees. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its legal entity in India is Advanced Neuro- Science Allies Private Limited (U85199KA2009PTC049821). Similar companies include Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical and 4 more; 9 of its 9 listed similar companies have raised funding.
Company details
ANSA was established in 2009 in Bengaluru, India, as an RD entity in the biotechnology sector. Focus is placed on stem cell research targeting neurological disorders, with the branded product anScell derived from healthy voluntary donors. Research-grade GMP-compliant mesenchymal stem cells are supplied for in vitro and research applications. A Tumor Tissue Repository for brain tumors is maintained to support cancer research. Backing is provided by Birthstone Capital.
- Headquarters Bengaluru, India
- Employees 18
- Founders N K Venkataramana
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ansaresearch.com
- Social X
- Legal Name Advanced Neuro- Science Allies Private Limited
- Date of Incorporation 12 May, 2009
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹25,000
FY 2023
- Net Loss-₹7,894
FY 2023 · -32% margin
- EBITDA-₹23,835
FY 2023 · -95% margin
- Employee Count18
Associated legal entities of Ansa Research
Ansa Research is associated with 2 registered companies on The Company Check; the primary company is Advanced Neuro- Science Allies Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Advanced Neuro- Science Allies Private Limited CIN U85199KA2009PTC049821 | Active | 12 May 2009 | Bangalore, Karnataka | ₹0.0 Cr | 18 | 3 | View details |
| Ans Private Limited CIN U67120GJ1999PTC035472 | Active | 23 Feb 1999 | Gandhinagar, Gujarat | ₹78.4 Cr | 17 | 7 | View details |
Board of directors of Advanced Neuro- Science Allies Private Limited (Ansa Research)
Advanced Neuro- Science Allies Private Limited is the primary company behind Ansa Research. The boards of the 2 registered companies of Ansa Research currently have 7 directors; the longest-serving is Jayeshbhai Natwarlal Sheth, appointed in 1999. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jayeshbhai Natwarlal Sheth DIN 00002162 | Managing Director | 23 Feb 1999 | 27 yrs 7 mo | Ans Private Limited |
| Ajaykumar Natvarlal Sheth DIN 00002163 | Whole-time director | 23 Feb 1999 | 27 yrs 7 mo | Ans Private Limited |
| Komal Ajaykumar Sheth DIN 00002164 | Director | 29 Oct 2003 | 22 yrs 11 mo | Ans Private Limited |
| Neelam Krishnan Venkataramana DIN 01894807 | Director | 12 May 2009 | 17 yrs 5 mo | Advanced Neuro- Science Allies Private Limited |
| Sripada Venkata Joga Rao DIN 03431654 | Director | 01 Nov 2010 | 15 yrs 11 mo | Advanced Neuro- Science Allies Private Limited |
| Raghavendra Sridhar Murthy DIN 08333186 | Director | 01 Jul 2021 | 5 yrs 3 mo | Advanced Neuro- Science Allies Private Limited |
| Mahavir Prasad Toshniwal DIN 00093584 | CFO | 01 Jul 2024 | 2 yrs 3 mo | Ans Private Limited |
People of Ansa Research
1 people are tracked at Ansa Research (1 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
N K Venkataramana | Founder & MD | Leadership |
Complete people profiles for Ansa Research
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Ansa Research
Figures of Advanced Neuro- Science Allies Private Limited, the primary company behind Ansa Research, for FY 2023. Revenue was ₹25,000. Net loss was -₹7,894 (-32% margin). EBITDA was -₹23,835 (-95% margin). Revenue has grown at a compounded annual rate of +10% over three years and -65% over five years.
- ₹25,000Revenue · FY 2023
- -₹7,894Net loss · -32% margin
- -₹23,835EBITDA · -95% margin
- ₹1.70 CrPaid-up capital
- 18Employees (provident fund records)
- +10%Revenue CAGR, 3 years
- -65%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Advanced Neuro- Science Allies Private Limited are on its company page.
Detailed financial statements for Ansa Research
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Ansa Research
Ansa Research has 9 listed similar companies in our database, 9 of them funded. They include Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| pacira.com | 2006 | Parsippany Troy Hills, United States | $85M | 712 | Injectable non-opioid products for post-surgical pain control are developed. |
Detailed similar companies of Ansa Research
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Ansa Research (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ansa Research
Ansa Research was founded in 2009.
Ansa Research is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Ansa Research has 18 employees.
The primary company behind Ansa Research, Advanced Neuro- Science Allies Private Limited, reported revenue of ₹25,000 for FY 2023.
ANSA was established in 2009 in Bengaluru, India, as an RD entity in the biotechnology sector. Focus is placed on stem cell research targeting neurological disorders, with the branded product anScell derived from healthy voluntary donors. Research-grade GMP-compliant mesenchymal stem cells are supplied for in vitro and research applications. A Tumor Tissue Repository for brain tumors is maintained to support cancer research. Backing is provided by Birthstone Capital.
Ansa Research's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Ansa Research is associated with 2 legal entities: Advanced Neuro- Science Allies Private Limited, Ans Private Limited.
The legal entities of Ansa Research currently have 9 directors, including Jay Kishorbhai Kular, Mahavir Prasad Toshniwal, Komal Ajaykumar Sheth and others.